What, in your view, are the indications and clinical phenotypes with MAC lung disease in which the FDA-approved amikacin liposome inhalation suspension is most like to achieve microbial conversion and improve clinical outcomes?

Name: What, in your view, are the indications and clinical phenotypes with MAC lung disease in which the FDA-approved amikacin liposome inhalation suspension is most like to achieve microbial conversion and improve clinical outcomes?
Uploaded: 2019-07-30T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Mehdi Mirsaeidi, MD, MPH

Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary